Drug Profile
Salbutamol dry-powder inhalation - Acerus Pharmaceuticals
Alternative Names: Albuterol dry-powder inhalation - Acerus Pharmaceuticals; Albuterol sulfate; Albuterol sulfate DPI; Albuterol sulfate DPI - Acerus Pharmaceuticals; Albuterol sulfate dry-powder inhalation - Acerus Pharmaceuticals; TBS-7Latest Information Update: 23 Dec 2021
Price :
$50
*
At a glance
- Originator Trimel Biopharma
- Developer Acerus Pharmaceuticals Corporation
- Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules; Tocolytics
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Asthma
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 09 Mar 2018 Acerus withdraws a phase II trial in Asthma prior to enrolment in USA (NCT01252758)
- 08 Sep 2015 Trimel Pharmaceuticals is now called Acerus Pharmaceuticals
- 04 Mar 2015 Phase I development is ongoing in Canada